Table of Content - Dermatomyositis Drug Market

Dermatomyositis (DM) is a rare inflammatory muscle disease that affects both the muscles as well as the skin. Dermatomyositis can strike people of all races, genders, and ages. Although, both males and females are affected equally in childhood, it is more common in females in adults. The exact cause of DM is unknown but it is believed to result from an immune-mediated process triggered by outside factors (e.g. malignancy, drugs, and infectious Drug Types) in genetically predisposed individuals. Dermatomyositis can occur with other connective tissue disorders such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren’s syndrome, and mixed connective tissue disease.

Market Dynamics

Key players operating in the global dermatomyositis drug market are focusing on adoption of growth strategies such as product approvals which is expected to drive the market growth during the forecast period. For instance, in July 2018, Corbus Pharmaceuticals Holdings, Inc., a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases, announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoid-mimetic drug, for the treatment of dermatomyositis. Moreover, increasing research and development activities by key players for the treatment of dermatomyositis which is expected to drive the market growth over the forecast period. For instance, on October 21, 2019, CSL Behring,a biopharmaceutical company initiated phase 3 Study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra) in adults with dermatomyositis (DM). The study is estimated to be completed in February 2024.

Key features of the study:

This report provides an in-depth analysis of the global dermatomyositis drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dermatomyositis drug market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
Key companies covered as a part of this study include Pfizer Inc., Teva Pharmaceuticals USA, Inc., Hikma Pharmaceuticals PLC, Asahi Kasei Corporation., Octapharma USA, Healthcare Pharmaceuticals Limited., Zydus Cadila, Alkem Laboratories Ltd, Apotex Inc, Eli Lilly and Co, and F.Hoffman-La Roche Ltd
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dermatomyositis drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dermatomyositis drug market

Detailed Segmentation:

Global Dermatomyositis Drug Market, By Drug Type:
- Corticosteroids
- Immunosuppressive Agents
- Others
Global Dermatomyositis Drug Market, By Route of Administration:
- Oral
- Topical
- Others
Global Dermatomyositis Drug Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Dermatomyositis Drug Market, By Region:
- North America
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Country
    - South Africa
    - Central Africa
    - North Africa
Company Profiles
- Pfizer Inc *
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceuticals USA, Inc.
- Hikma Pharmaceuticals PLC
- Asahi Kasei Corporation
- Octapharma USA
- Healthcare Pharmaceuticals Limited
- Zydus Cadila
- Alkem Laboratories Ltd
- Apotex Inc
- Eli Lilly and Co
- F.Hoffman-La Roche Ltd

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Market Snapshot, By Drug Type
  - Market Snapshot, By Route of Administration
  - Market Snapshot, By Distribution Channels
  - Market Snapshot, By Region
- Coherent Opportunity Map (COM)
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunity
- Impact Analysis
- Regulatory Scenario
- Market Trends
- Key Developments
- Epidemiology
- PEST Analysis
- Collaboration and Acquisition
- Porters Analysis
- Pipeline Analysis
Global Dermatomyositis Drug Market – Impact of Coronavirus (COVID-19) Pandemic
- Economic Impact
- Impact on Demand and Supply
- COVID-19 Impact Assessments
Global Dermatomyositis Drug Market, By Drug Type, 2017-2030, (US$ Mn)
- Introduction
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Corticosteroids
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Immunosuppressive Agents
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Mn)
Global Dermatomyositis Drug Market, By Route of Administration, 2017-2030, (US$ Mn)
- Introduction
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Oral
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Topical
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Others
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Global Dermatomyositis Drug Market, By Distribution Channel, 2017-2030, (US$ Mn)
- Introduction
  - Market Share Analysis, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, 2017 – 2030
  - Segment Trends
- Hospital Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Retail Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
- Online Pharmacy
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2017-2030,(US$ Million)
Global Dermatomyositis Drug Market, By Region, 2017-2030, (US$ Mn)
- Introduction
  - Market Share Analysis, By Region, 2022 and 2030 (%)
  - Y-o-Y Growth Analysis, For Regions, 2017–2030
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    - U.K.
    - Germany
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Countries, 2017-2030,(US$ Mn)
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017-2030,(US$ Mn)
  - Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017-2030,(US$ Mn)
    - North Africa
    - Central Africa
    - South Africa
Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
  - Pfizer Inc.*
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Teva Pharmaceuticals USA, Inc.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Hikma Pharmaceuticals PLC
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Asahi Kasei Corporation.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Octapharma USA
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Healthcare Pharmaceuticals Limited.
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Zydus Cadila
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Alkem Laboratories Ltd
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Apotex Inc
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Eli Lilly and Co
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
  - Hoffman-La Roche Ltd
    - Company Highlights
    - Product Portfolio
    - Key Highlights
    - Financial Performance
    - Strategies
Section
- Research Methodology
- About us

*Browse 28 market data tables and 32 figures on "Global Dermatomyositis Drug Market” - Forecast to 2030

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

Need a Custom Report?

EXISTING CLIENTELE